Effect of aflibercept on proliferative vitreoretinopathy: Proteomic analysis in an experimental animal model

被引:5
|
作者
Uslubas, Isil [1 ,3 ]
Kanli, Aylin [2 ]
Kasap, Murat [2 ]
Akpinar, Gurler [2 ]
Karabas, Levent [1 ]
机构
[1] Kocaeli Univ, Dept Ophthalmol, Sch Med, Kocaeli, Turkey
[2] Kocaeli Univ, Dept Med Biol, Sch Med, Kocaeli, Turkey
[3] Golcuk Necati Celik State Hosp, TR-41650 Kocaeli, Turkey
关键词
Proliferative vitreoretinopathy; Aflibercept; Dispase; Proteomic; Animal model;
D O I
10.1016/j.exer.2020.108425
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The aim of this study was to monitor inflammatory, proliferative and progressive effects of proliferative vitreoretinopathy (PVR) and aflibercept treatment in dispase induced PVR rat model by proteomic analysis. Material and methods: A total of 35 male Long Evans pigmented rats were divided into three groups, namely, PVR (dispase+saline), PVR+aflibercept (dispase+aflibercept) and control. The PVR group received 2 mu l of 0.03 IU/mu l dispase and 2 mu l saline, the PVR+aflibercept group received 2 mu l of 0.03 IU/mu l and 2 mu l of 40 mg/ml aflibercept at the first day of the experiment. At the end of the 6th week all retina and vitreous specimens were collected by evisceration and transferred to the proteomics laboratory for analysis. Proteomic analysis by 2D gel electrophoresis coupled with MALDI-TOF/TOF was performed. Results: In the PVR and PVR+aflibercept group 16 different proteins that were identified to be differentially regulated in comparison to the control group. In the PVR+aflibercept group, ENO1, ENO2, LDH-B, PEBP-1 and GS levels were higher than the PVR group. In addition, the association of proteins such as UCHL, PEBP1, PDHB and ENO1 with PVR has been demonstrated for the first time. Conclusion: STRING analysis elucidated the functional protein-protein interaction among the differentially regulated proteins and highlighted that those proteins mainly played roles in carbon and nucleotide metabolisms. Functional analysis of the differentially regulated proteins indicated the presence of inflammation, gliosis and retinal damage in the PVR group. Aflibercept treatment had pronounced effect on prevention of inflammation and retinal damage while causing a slight increase in gliosis. However, aflibercept treatment was not effective enough to normalize the levels of differentially regulated proteins of the PVR group. Therefore, we predict that the treatment dose of aflibercept used in this study was below of its ideal concentration and should be increased in the future studies. The differential regulation of these structural proteins in this study should shed some light to the mechanism of glial wound formation in the retina and guide future treatment modalities.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Vitreous proteomic analysis of proliferative vitreoretinopathy
    Yu, Jing
    Liu, Feng
    Cui, Shu-Jian
    Liu, Yan
    Song, Zheng-Yu
    Cao, Hui
    Chen, Feng-E
    Wang, Wei-Jun
    Sun, Tao
    Wang, Fang
    PROTEOMICS, 2008, 8 (17) : 3667 - 3678
  • [2] The proteomic profile of a mouse model of proliferative vitreoretinopathy
    Markus, Bernadett
    Pato, Zsuzsanna
    Sarang, Zsolt
    Albert, Reka
    Tozser, Jozsef
    Petrovski, Goran
    Csosz, Eva
    FEBS OPEN BIO, 2017, 7 (08): : 1166 - 1177
  • [3] The effect of infliximab and octreotide on cytokine levels experimental proliferative vitreoretinopathy
    Savur, Fatma
    Aydemir, Orhan
    Ilhan, Nevin
    CUTANEOUS AND OCULAR TOXICOLOGY, 2020, 39 (01) : 61 - 66
  • [4] A mouse model of proliferative vitreoretinopathy induced by dispase
    Soler, MVC
    Gallo, JE
    Dodds, RA
    Suburo, AM
    EXPERIMENTAL EYE RESEARCH, 2002, 75 (05) : 491 - 504
  • [5] The role of retinotomy in an experimental rabbit model of proliferative vitreoretinopathy
    Goldaracena, MB
    GarciaLayana, A
    Pastor, JC
    Saornil, MA
    delaFuente, F
    Gayoso, MJ
    CURRENT EYE RESEARCH, 1997, 16 (05) : 422 - 427
  • [6] Animal Models of Proliferative Vitreoretinopathy and Their Use in Pharmaceutical Investigations
    Hou, Huiyuan
    Nudleman, Eric
    Weinreb, Robert N.
    OPHTHALMIC RESEARCH, 2018, 60 (04) : 195 - 204
  • [7] Experimental gene therapy for an in vitro model of proliferative vitreoretinopathy
    Wong, CA
    Jia, W
    Matsubara, JA
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 1999, 34 (07): : 379 - 384
  • [8] ANTIPROLIFERATIVE EFFECT OF RETINOIC ACID IN INTRAVITREOUS SILICONE OIL IN AN ANIMAL-MODEL OF PROLIFERATIVE VITREORETINOPATHY
    ARAIZ, JJ
    REFOJO, MF
    ARROYO, MH
    LEONG, FL
    ALBERT, DM
    TOLENTINO, FI
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1993, 34 (03) : 522 - 530
  • [9] Effect of different fixative solutions on eyes with experimental proliferative vitreoretinopathy
    Nassar, Khaled
    Lueke, Julia
    Lueke, Matthias
    Kamal, Mahmoud
    Soliman, Mahmoud M.
    Grisanti, Salvatore
    Grisanti, Swaantje
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2015, 96 (02) : 103 - 110
  • [10] Interleukin 1 in experimental proliferative vitreoretinopathy
    Osusky, R
    Tao, L
    Ryan, SJ
    OPHTHALMOLOGICA, 1997, 211 (01) : 49 - 52